Sorafenib liver transplant trial posts results; Bayer renal study still completed

The notable update this week is results posting for a long-running sorafenib trial in liver transplant recipients, where Bayer serves as collaborator.

• "Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer" (NCT01624285) is a Phase 2, randomized, placebo-controlled study led by Jonsson Comprehensive Cancer Center with Bayer as collaborator. The trial tests sorafenib adjuvant therapy in high risk orthotopic liver transplant recipients with hepatocellular carcinoma.¹ The study enrolled 73 participants, reached primary and study completion in February 2023, and results were first posted on 2026-11-03.¹ The primary objective was two-year recurrence free survival.¹
• Bayer's diagnostic methodology study on kidney function, "Study to Investigate Renal Functional Reserve in Healthy Participants and in Participants With Impaired Renal Function,"² remains listed as completed, with no new status change. The study collected and analyzed kidney function information from up to 50 adults, including healthy people and people with stable kidney problems,² with enrollment reaching 33 participants and both primary and study completion reached on 2026-09-09.